**Core Concept**
Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) are complications of diabetes mellitus affecting the retina. Various pharmacological agents are used to manage these conditions, including anti-vascular endothelial growth factor (anti-VEGF) agents, corticosteroids, and hypoglycemic agents. The treatment aims to reduce edema, prevent vision loss, and promote retinal health.

**Why the Correct Answer is Right**
Anti-VEGF agents, such as ranibizumab, bevacizumab, and aflibercept, are commonly used in the treatment of DME and DR. These agents work by inhibiting the VEGF pathway, which is involved in angiogenesis and vascular permeability. Corticosteroids, like triamcinolone, are also used to reduce inflammation and edema in the retina. Hypoglycemic agents, such as metformin and sulfonylureas, are used to manage diabetes mellitus, which is the underlying cause of DME and DR.

**Why Each Wrong Option is Incorrect**
* **Option A:** This is a correct treatment option for DME and DR. Anti-VEGF agents are a mainstay of treatment for these conditions.
* **Option B:** This is also a correct treatment option for DME and DR. Corticosteroids are used to reduce inflammation and edema in the retina.
* **Option C:** This is not a correct treatment option for DME and DR. While metformin is used to manage diabetes mellitus, it is not a direct treatment for DME and DR.

**Clinical Pearl / High-Yield Fact**
It's essential to distinguish between the underlying cause of DME and DR (diabetes mellitus) and the treatment of the complications themselves. Hypoglycemic agents like metformin are used to manage diabetes, but not as a direct treatment for DME and DR.

**Correct Answer: C. Metformin is used to manage diabetes mellitus, but not as a direct treatment for Diabetic Macular Edema/Retinopathy.**